The company said it grew at 7.8% in Q3 FY22 as compared to IPM growth of 5.7%, outperforming IPM in cardio-metabolic, CNS & women's health therapies.
Shares of Eris Lifesciences were trading 0.36% lower at Rs 706.30 on BSE. The result was announced during market hours today, 28 January 2022.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.